

Substitute for form 1449A/PTO

FEB 27 2003

ATTORNEY'S DKT No.
002010-603APPLICATION No.
09/127,364INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Yednock, et al.FILING DATE
July 31, 1998GROUP
1653


U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Patent Document		Sub Class	Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Class Code (if known)			
DL	4,018,913	514	20	Okamoto et al.	04-19-1977
	4,018,915	514	20	Okamoto et al.	04-19-1977
	4,036,955	514	20	Okamoto et al.	07-19-1977
	4,041,156	514	20	Okamoto et al.	08-19-1977
	4,046,876	514	20	Okamoto et al.	09-06-1977
	4,055,636	514	20	Okamoto et al.	10-25-1977
	4,055,651	514	319	Okamoto et al.	10-25-1977
	4,069,318	514	20	Okamoto et al.	01-17-1978
	4,070,457	514	510	Okamoto et al.	01-24-1978
	4,071,621	514	20	Okamoto et al.	01-31-1978
	4,073,914	514	319	Kikumoto et al.	02-14-1978
	4,096,255	514	227.5	Kikumoto et al.	06-20-1978
	4,097,591	514	20	Okamoto et al.	06-27-1978
	4,104,392	514	307	Okamoto et al.	08-01-1978
	4,260,601	514	19	Reichelt	04-07-1981
DL	4,804,676	514	423	Inaoka, et al.	02-14-1989
	4,910,190	514	19	Bergeson, et al.	03-20-1990
	4,977,168	514	19	Bernat et al.	12-11-1990
	4,981,873	514	562	Witte, et al.	01-01-1991
	4,992,421	514	19	De	02-12-1991
	5,338,755	514	414	Wagnon, et al.	08-16-1994
	5,362,902	560	13	Barnish, et al.	11-08-1994
	5,397,801	514	418	Wagnon, et al.	03-14-1995
	5,481,005	548	537	Wagnon, et al.	01-02-1996
	5,578,633	514	418	Wagnon, et al.	11-26-1996
	5,650,428	514	419	Ohmori, et al.	07-22-1997
	5,688,913	530	330	Arrhenius, et al.	11-18-1997
	6,001,809	514	15	Thorsett et al.	12/14/1999
	6,093,696	514	19	Head et al.	07/25/2000
	6,110,945	514	332	Head et al.	08/29/2000
DL	6,197,794	514	342	Head et al.	02/06/2001
	6,221,888	514	357	Durette, et al.	04-24- 2001
	6,229,011	544	171	Chen et al.	05/08/2001
	6,239,108	514	15	Lin et al.	05/29/2001

RECEIVED
MAR 09 2003

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

David L. Litten

1/5/04




Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY'S DKT No.
002010-603APPLICATION No.
09/127,364APPLICANT
Yednock, et al.FILING DATE
July 31, 1998GROUP
1653

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
DL	92/16549		WIPO	10-01-1992		
	94/07815		WIPO	04-14-1994		
	94/12181		WIPO	06-09-1994		
	95/15973		WIPO	06-15-1995		
	96/01644		WIPO	01-25-1996		
	96/20725		WIPO	07-11-1996		
	96/20949		WIPO	07-11-1996		
	96/22966		WIPO	08-01-1996		
	97/03094		WIPO	01-30-1997		
	97/48726		WIPO	12-24-1997		
	98/04247		WIPO	02-05-1998		
	98/42656		WIPO	10-01-1998		
	98/53814		WIPO	12-03-1998		
	98/53817		WIPO	12-03-1998		
	98/53818		WIPO	12-03-1998		
DL	98/54207		WIPO	12-03-1998		
	98/58902		WIPO	12-30-1998		
	99/06432		WIPO	02-11-1999		
	99/06436		WIPO	02-11-1999		
	99/10312		WIPO	03-04-1999		
	99/10313		WIPO	03-04-1999		
	99/67230		WIPO	12-29-1999		
	6147073		Australia	04-17-1975		
	23 57 334		Germany	06-06-1974		
	26 55 636		Germany	06-23-1977		
DL	0 526 348		EPO	02-03-1993		
	9714314.3		Great Britain	07-07-1997		
	9714316.8		Great Britain	07-07-1997		
	9714335.8		Great Britain	07-07-1997		
	9711143.9		Great Britain	05-30-1997		
	9722674.0		Great Britain	10-27-1997		
	9800680.2		Great Britain	01-14-1998		
	9800684.4		Great Britain	01-14-1998		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

David Peter 1/5/04



SHEET 4 OF 6

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY'S DKT NO.
002010-603APPLICATION NO.
09/127,364APPLICANT
Yednock, et al.FILING DATE
July 31, 1998GROUP
1653

TECH CENTER 1600/2910

MAR 03 2003

RECEIVED

9800686.9	Great Britain	01-14-1998
04 154732	Japan	05-27-1992
06 016625	Japan	01-25-1994
08 073422	Japan	03-19-1996


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
OK	ARCHIBALD, S.C., et al., "Discovery and Evaluation of Potent, Tyrosine-Based $\alpha 4 \beta 1$ Integrin Antagonists", <i>Bioorg & Med. Chem. Lett.</i> , Vol. 10, pp. 997-999 (2000).
	CROSSLEY, M.J., et al. "Studies on the Effects of Pharmacological Agents on Antigen-Induced Arthritis in BALB/c Mice." <i>Drugs Exptl. Clin. Res.</i> XIII(5): 273-277 (1987).
	DUTTA, A.S., et al. "Potent Cyclic Monomeric and Dimeric Peptide Inhibitors of VLA-4 ($\alpha 4 \beta 1$ Integrin)-Mediated Cell Adhesion Based on the Ile-Leu-Asp-Val Tetrapeptide." <i>J. Peptide Sci.</i> 6: 321-341 (2000).
OK	EL-NAGGAR, A.M., et al., <i>Acta. Pharm. Jugosl.</i> (1985), 35(1), 15-22.
	ENGLEMAN, V.W., et al. "Cell Adhesion Integrins as Pharmaceutical Targets." <i>Ann. Reports in Med. Chem.</i> 31: 191-200 (1996).
	EWENSON, A. et al., "Analogues of Substance P Containing an α -hydroxy, β -amino acid: Synthesis and Biological Activity", <i>Eur. J. Med. Chem.</i> , Vol. 26, pp. 435-442 (1991).
	FOTOUHI, N., et al., "The Design and Synthesis of Potent Cyclic Peptide VCAM-VLA-4 Antagonists Incorporating an Achiral Asp-Pro Mimetic", <i>Bioorg & Med. Chem. Lett.</i> , Vol. 10, pp. 1171-1173 (2000).
OK	HAUBNER, R., et al. "Cyclic RGD Peptides Containing β -Turn Mimetics." <i>J. Am. Chem. Soc.</i> 118: 7881-7891 (1996).
	HAUPTMANN, J., et al. "Degradation of a Benzamidine-Type Synthetic Inhibitor of Coagulation Enzymes in Plasma of Various Species." <i>Thrombosis Research.</i> 61: 279-284 (1991).
	HAWORTH, D., et al. "Anti-inflammatory activity of c(ILDV-NH(CH ₂) ₅ CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion." <i>Br. J. Pharmacol.</i> 126: 1751-1760 (1999).
	JACKSON, D.Y., et al., "Potent $\alpha 4 \beta 1$ Peptide Antagonists as Potential Anti-Inflammatory Agents", <i>J. Med. Chem.</i> , Vol. 40, pp. 3359-3368 (1997).
OK	KATO, Y., et al., "Oxidative Degradation of Collagen and Its Model Peptide by Ultraviolet Irradiation", <i>J. Agric. Food Chem.</i> , Vol. 40, pp. 373-379 (1992).
	KOMORIYA, A., et al. "The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine." <i>J. Biol. Chem.</i> 266(23): 15075-15079 (1991).

D. Rubin

1/5/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



SHEET 5 OF 6

Substitute for form 1449A/PTO


ATTORNEY'S DKT No.
002010-603APPLICATION No.
09/127,934INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Yednock, et al.FILING DATE
July 31, 1998GROUP
1653RECEIVED
MAR 9 2003
FEB 18 2003

	KUDLACZ, E., et al., "Pulmonary Eosinophilia in a Murine Model of Allergic Inflammation is Attenuated by Small Molecule $\alpha 4 \beta 1$ Antagonists", <i>J. of Pharm and Exp. Ther.</i> , Vol. 300 No. 2, pp. 747-752.
	KUROKAWA, M., et al. "Synthesis and Antiinflammatory Activity of <i>cis</i> - and <i>trans</i> -6,6a,7,8,9,10,10a,11-Octahydro-11-oxodibenzo[<i>b,e</i>]thiepinacetic and -oxepinacetic Acids." <i>J. Med. Chem.</i> 33: 504-509 (1990).
	LEIBFRITZ, D., et al., <i>Tetrahedron</i> (1982), 38(14), 2165-81.
	LIN, K., et al., "Selective, Tight-Binding Inhibitors of Integrin $\alpha 4 \beta 1$ that Inhibit Allergic Airway Responses", <i>J. Med. Chem.</i> , Vol. 42, pp. 920-934.
	MÜLLER, G., et al., "Discovery and Evaluation of Piperidinyl Carboxylic Acid Derivatives as Potent $\alpha 4 \beta 1$ Integrin Antagonists", <i>Bioorg. & Med. Chem. Lett.</i> , ol. 11, pp. 3019-3021 (2001).
	PAPAIIOANNOU, D., et al., "Facile Preparation of the 1-Hydroxybenzotriazolyl Ester of <i>N</i> -Tritylpyroglutamic Acid and its Application to the Synthesis of TRH, [D-His ²]TRH and Analogues Incorporating <i>cis</i> - and <i>trans</i> -4-Hydroxy-L-Proline", <i>Acta Chem. Scand.</i> , Vol. 49, pp. 103-114 (1995).
	PERI, F., et al., "Assembly of Binding Loops on Aromatic Templates as VCAM-1 Mimetics", <i>J. of Peptide Sci.</i> , Vol. 5, pp. 313-322 (1999).
	SIMANIS, V. et al., <i>Int. J. Pept. Protein Res.</i> (1982), 19(1), 67-70.
	SOUERS, A.J., et al., "Novel Inhibitors of $\alpha 4 \beta 1$ Integrin Receptor Interactions Through Library Synthesis and Screening", <i>Bioorg. & Med. Chem. Lett.</i> , Vol. 8, pp. 2297-2302 (1998)
	TAIT, A., et al. "Synthesis and Antiinflammatory Activity of 2,6-Bis(1,1-Dimethylethyl)Phenol Derivatives." <i>Il Farmaco.</i> 48(10): 1463-1473 (1993).
	UREN, M.F., et al. "The Effect of Anti-Inflammatory Agents on the Clinical Expression of Bovine Ephemeral Fever." <i>Veterinary Microbiology.</i> 19: 99-111 (1989).
	van der Laan, LJW, et al., "Beneficial Effect of Modified Peptide Inhibitor of $\alpha 4$ Integrins on Experimental Allergic Encephalomyelitis in Lewis Rats", <i>J. of Neurosci. Res.</i> , Vol. 67, pp. 191-199 (2002).
	VATISTAS, N.J., et al. "Infection of the intertubercular bursa in horses: four cases (1978-1991)." <i>J. Am. Vet. Med. Assoc.</i> 208(9): 1434-1437 (1996).
	VOIGT, B., et al. "Synthese von $N\alpha$ -(Arylsulfonyl-L-prolyl)-und $N\alpha$ -Benzyloxycarbonyl-L-prolyl)-D,L-4-amidinophenyl-alaninamiden als Thrombininhibitoren." <i>Pharmazie.</i> 41: 233-235 (1986).
	YANG, Y., et al. "LPAM-1 (integrin $\alpha 4 \beta 7$)-ligand binding: overlapping binding sites recognizing VCAM-1, MadCAM-1 and CS1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides." <i>Eur. J. Immunol.</i> 28: 995-1004 (1998).
	Chemical Abstract No. 126040, Vol. 74, No. 23 (June 7, 1971).
	Chemical Abstract No. 176262, Vol. 99, No. 21 (November 21, 1983).
	Chemical Abstract No. 210288, Vol. 106, No. 25 (June 22, 1987).
	Chemical Abstract No. 167952, Vol. 108, No. 19 (May 9, 1988).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

David A. Brown 1/5/04

(05/01)



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTORNEY'S DKT NO. 002010-603	APPLICATION NO. 09/127,364
	APPLICANT Yednock, et al.	
	FILING DATE July 31, 1998	GROUP 1653

	Chemical Abstract No. 34164, Vol. 125, No. 3 (July 15, 1996).		
	Chemical Abstract No. 211689, Vol. 117 (1992) Gamo.		
Examiner Signature		Date Considered	

David Latta

1/5/04

RECEIVED
MAR 9 8 2003
TECH CENTER 1600/2800